skip to content


Issue No. 29 | December 16, 2016

News and Features

Updates to the Pediatric Opportunistic Infections Guidelines

The following sections of the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children have recently been updated:

  • Human Herpesvirus 8: A new graded recommendation has been added recommending that chemotherapy, along with continuation of antiretroviral therapy (ART), be provided to children with Kaposi sarcoma-related immune reconstitution syndrome. This recommendation is based on studies in HIV-infected adults with Kaposi sarcoma-associated immune reconstitution syndrome that found that addition of chemotherapy to ART was associated with reduced mortality compared with ART alone.
  • Microsporidiosis: A graded recommendation has been added recommending use of systemic fumagillin (where available) in addition to ART for microsporidiosis caused by Enterocytozoon bieneusi and Vittaforma corneae. The recommendation for use of oral albendazole in addition to topical fumagillin for keratoconjunctivitis has been limited to infections caused by microsporidia other than Enterocytozoon bieneusi and Vittaforma corneae, because of lack of activity of albendazole against these species.
For more information, please see What’s New in the Guidelines.

Pediatric HIV/AIDS Training Course Opportunity

The American Academy of Pediatrics, St. Jude Children’s Research Hospital, and the Pediatric Infectious Diseases Society will be hosting a pediatric HIV/AIDS training course on March 7-8, 2017, in Memphis, TN. Core concepts in pediatric HIV/AIDS care will be taught in large group sessions and then followed by case-based workshops and interactive sessions which reinforce and highlight complicated case management. The target audience is nurses, residents, and fellows in training, as well as clinicians (physicians, advanced practice nurses, and physician assistants) looking for a refresher course on pediatric HIV/AIDS care designed in accordance with U.S. perinatal HIV transmission and pediatric/adolescent HIV/AIDS care guidelines.

Registration for the course is $350.

For more information visit: